Sandro Pignata

1996–2025 年に発表

197
論文数
26,358
被引用数
77
h 指数
180
i10 指数

被引用数

Sandro Pignata の年別被引用数1988 年: 被引用 2 件1997 年: 被引用 1 件1998 年: 被引用 1 件2000 年: 被引用 18 件2001 年: 被引用 38 件2002 年: 被引用 30 件2003 年: 被引用 30 件2004 年: 被引用 23 件2005 年: 被引用 31 件2006 年: 被引用 35 件2007 年: 被引用 32 件2008 年: 被引用 28 件2009 年: 被引用 25 件2010 年: 被引用 30 件2011 年: 被引用 41 件2012 年: 被引用 46 件2013 年: 被引用 38 件2014 年: 被引用 63 件2015 年: 被引用 40 件2016 年: 被引用 74 件2017 年: 被引用 96 件2018 年: 被引用 132 件2019 年: 被引用 691 件2020 年: 被引用 1,117 件2021 年: 被引用 1,215 件2022 年: 被引用 1,145 件2023 年: 被引用 1,110 件2024 年: 被引用 1,823 件2025 年: 被引用 910 件2026 年: 被引用 25 件1989〜1996 年は被引用が無いため表示していません1999 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,038 件、この内訳の 19.3%中国: 引用元論文 1,155 件、この内訳の 11%イタリア: 引用元論文 886 件、この内訳の 8.4%イギリス: 引用元論文 679 件、この内訳の 6.4%フランス: 引用元論文 515 件、この内訳の 4.9%ドイツ: 引用元論文 431 件、この内訳の 4.1%スペイン: 引用元論文 425 件、この内訳の 4%カナダ: 引用元論文 410 件、この内訳の 3.9%日本: 引用元論文 357 件、この内訳の 3.4%オランダ: 引用元論文 285 件、この内訳の 2.7%オーストラリア: 引用元論文 276 件、この内訳の 2.6%韓国: 引用元論文 244 件、この内訳の 2.3%
0%19.3%その他 27%

分野

  • Medicine75.5%
  • Biochemistry, Genetics and Molecular Biology16.9%
  • Immunology and Microbiology3.7%
  • Materials Science0.9%
  • Economics, Econometrics and Finance0.8%
  • Engineering0.7%
  • その他1.5%

トピック

  • Ovarian cancer diagnosis and treatment11.3%
  • PARP inhibition in cancer therapy9.2%
  • Endometrial and Cervical Cancer Treatments5.1%
  • Cancer Immunotherapy and Biomarkers4.5%
  • DNA Repair Mechanisms2.7%
  • BRCA gene mutations in cancer2.4%
  • その他64.8%

共著者

全論文

検索で開く
  1. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2019 被引用: 2,040

  2. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2022 被引用: 893

  3. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Fiona Nussey, Andrew R. Clamp, Richard T. Penson, Amit M. Oza, A. Poveda Velasco, Manuel Rodrigues, Jean‐Pierre Lotz, Frédèric Selle, Isabelle Ray‐Coquard, Diane Provencher, Aleix Prat Aparicio, Laura Vidal Boixader, Clare L. Scott, Kenji Tamura, Mayu Yunokawa, Alla Lisyanskaya, Jacques Médioni, Nicolas Pécuchet, Coraline Dubot, Thibault De La Motte Rouge, Marie‐Christine Kaminsky, B. Weber, Alain Lortholary, Christine Parkinson, Jonathan A. Ledermann, Sarah Williams, Susana Banerjee, Jonathan A. Cosin, James Hoffman, Richard T. Penson, Marie Plante, Allan Covens, Gabe S. Sonke, Florence Joly, Anne Floquet, Susana Banerjee, Holger W. Hirte, Amnon Amit, Tjoung-Won Park-Simon, Koji Matsumoto, Sergei Tjulandin, Jae‐Hoon Kim, Laurence Gladieff, Roberto Sabbatini, David M. O’Malley, Patrick Timmins, Daniel Kredentser, Nuria Laínez Milagro, M.P. Barretina Ginesta, Ariadna Tibau Martorell, Alfonso Gómez de Liaño, Belén Ojeda González, Linda Mileshkin, Masaki Mandai, Ingrid Boere, Petronella B. Ottevanger, Joo‐Hyun Nam, Elias Abdo Filho, Salima Hamizi, Francesco Cognetti, David Warshal, Elizabeth Dickson-Michelson, Scott Kamelle, Nathalie D. McKenzie, Gustavo C. Rodriguez, Deborah K. Armstrong, Eva Chalas, Paul Celano, Kian Behbakht, Susan A. Davidson ほか 21 名 - The Lancet Oncology 2017 被引用: 1,863

  4. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , James Sun, Kevin Lin, Heidi Giordano, Jonathan A. Ledermann, Martin Buck, Andrew Dean, Michael Friedländer, Jeffrey C. Goh, Paul R. Harnett, Ganessan Kichenadasse, Clare L. Scott, Hannelore Denys, Luc Dirix, Ignace Vergote, Laurie Elit, Prafull Ghatage, Amit M. Oza, Marie Plante, Diane Provencher, Johanne I. Weberpals, Stephen Welch, Anne Floquet, Laurence Gladieff, Florence Joly, Alexandra Léary, Alain Lortholary, Jean‐Pierre Lotz, Jacques Médioni, Olivier Trédan, Benoît You, Ayşe Balat, Claudia Hänle, Petra Krabisch, Tanja Neunhöffer, Martin Pölcher, Pauline Wimberger, A Amit, Svetlana Kovel, Michelle Leviov, Tamar Safra, Ronnie Shapira‐Frommer, Salomon M. Stemmer, Alessandra Bologna, Nicoletta Colombo, Domenica Lorusso, Sandro Pignata, Roberto Sabbatini, Giovanni Scambia, Stefano Tamberi, Claudio Zamagni, Peter C.C. Fong, Anne O’Donnell, Margarita Amenedo, A. Casado Herráez, Jesús García-Donás, E.M. Guerra, Ana Oaknin, Isabel Palacio, Ignacio Romero, A Sanchez, Susana Banerjee, Andrew R. Clamp, Yvette Drew, Hani Gabra, D Jackson, JA Ledermann, Iain A. McNeish, C. A. Parkinson, Melanie Powell, Carol Aghajanian ほか 17 名 - The Lancet 2017 被引用: 1,704

  5. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 被引用: 414

  6. Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study

    著者: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 被引用: 372

  7. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

    著者: , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2019 被引用: 840

  8. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Antonio González-Martı́n, Viola Heinzelmann‐Schwarz, Florence Joly, J.W. Kim, Frédéric Kridelka, Jonathan A. Ledermann, Domenica Lorusso, Sven� Mahner, W. Glenn McCluggage, Iain A. McNeish, Mikio Mikami, Mansoor Raza Mirza, Philippe Morice, Shibani Nicum, Siel Olbrecht, Dearbhaile M. O’Donnell, Patricia Pautier, François Planchamp, Sandro Pignata, Denis Querleu, Isabelle Ray‐Coquard, Alexandros Rodolakis, Jalid Sehouli, Fatih Selçukbırıcık, Cristiana Sessa, Nilanchali Singh, David S.P. Tan, D. Timmerman, Germana Tognon, Jacobus van der Velden, Ignace Vergote, Petronella O. Witteveen, Alain G. Zeimet - Annals of Oncology 2019 被引用: 1,165

  9. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ugo De Giorgi, Maria Bjurberg, Michael A. Gold, David M. O’Malley, Brigitte Honhon, Christof Vulsteke, Eveline Cuypere, Hannelore Denys, Jean‐François Baurain, Claudio Zamagni, Meaghan Tenney, Mary E. Gordinier, William H. Bradley, Matthew Schlumbrecht, Nicola M. Spirtos, Nicole Concin, Sven Mahner, Giovanni Scambia, Charles A. Leath, Robin Farias‐Eisner, Joshua M. Cohen, Carolyn Muller, Sumeet Bhatia - The Lancet Oncology 2021 被引用: 394

  10. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2023 被引用: 339

  11. Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 被引用: 406

  12. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sarper Toker, Stephen J. O’Keefe, Sandro Pignata, Linda Duska - The Lancet 2024 被引用: 349

  13. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Giovanni Scambia, Maria Ornella Nicoletto, Fiona Nussey, Andrew R. Clamp, Richard T. Penson, Amit M. Oza, A. Poveda Velasco, Manuel Rodrigues, Jean‐Pierre Lotz, Frédèric Selle, Isabelle Ray‐Coquard, Diane Provencher, Aleix Prat Aparicio, Laura Vidal Boixader, Clare L. Scott, Kenji Tamura, Mayu Yunokawa, Alla Lisyanskaya, Jacques Médioni, Nicolas Pécuchet, Coraline Dubot, Thibault De La Motte Rouge, Marie‐Christine Kaminsky, B. Weber, Alain Lortholary, Christine Parkinson, Jonathan A. Ledermann, Sarah Williams, Susana Banerjee, Jonathan A. Cosin, James Hoffman, Richard T. Penson, Marie Plante, Allan Covens, Gabe S. Sonke, Florence Joly, Anne Floquet, Susana Banerjee, Holger W. Hirte, Amnon Amit, Tjoung-Won Park-Simon, Koji Matsumoto, Sergei Tjulandin, Jae‐Hoon Kim, Laurence Gladieff, Roberto Sabbatini, David M. O’Malley, Patrick Timmins, Daniel Kredentser, Nuria Laínez Milagro, M.P. Barretina Ginesta, Ariadna Tibau Martorell, Alfonso Gómez de Liaño, Belén Ojeda González, Linda Mileshkin, Masaki Mandai, Ingrid Boere, Petronella B. Ottevanger, Joo‐Hyun Nam, Elias Abdo Filho, Salima Hamizi, Francesco Cognetti, David Warshal, Elizabeth Dickson-Michelson, Scott Kamelle, Nathalie D. McKenzie, Gustavo C. Rodriguez, Deborah K. Armstrong, Eva Chalas, Paul Celano ほか 23 名 - The Lancet Oncology 2021 被引用: 416

  14. ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , José Alejandro Pérez Fidalgo, Sandro Pignata, Pedro T. Ramírez, Isabelle Ray‐Coquard, Ignacio Romero, Giovanni Scambia, Jalid Sehouli, Ronnie Shapira‐Frommer, Sudha Sundar, David S.P. Tan, Çağatay Taşkıran, Willemien J. van Driel, Ignace Vergote, François Planchamp, Cristiana Sessa, Anna Fagotti - Annals of Oncology 2024 被引用: 284

  15. The forefront of ovarian cancer therapy: update on PARP inhibitors

    著者: , , , , , , - Annals of Oncology 2020 被引用: 370

  16. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial

    著者: , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2022 被引用: 154

  17. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sven� Mahner, Alexander Reuß, Andreas du Bois, Christoph Grimm, Christian Marth, Regina Berger, Nicole Concin, Ting‐Chang Chang, Kazunori Ochiai, Val Gebski, Alison Davis, Philip Beale, Ignace Vergote, Frédéric Kridelka, Hannelore Denys, Vincent Vandecaveye, Francisco José Cândido dos Reis, Maria Del Pilar Estevez-Diz, Gavin Stuart, Helen Mackay, Mark S. Carey, David Cibula, Pavel Dundr, Oliver Dorigo, Jonathan S. Berek, Dearbhaile M. O’Donnell, Feras Abu Saadeh, Ingrid Boere, Christianne Lok, Pluvio Coronado, Nelleke Ottevanger, David S.P. Tan, Joseph Ng, Antonio Gonzalez Martin, Ana Oaknin, Andrés Poveda, Alejandro Perez Fidalgo, Alejandro Rauh-Hain, Karen H. Lu, Carlos López-Zavala, Eva María Gómez-García, Isabelle Ray-Coquard, Xavier Paolettí, Jean‐Emmanuel Kurtz, Florence Joly, Bénédicte Votan, Michael A. Bookman, Kathleen Moore, Rebecca C. Arend, Keiichi Fujiwara, Hiroyuki Fujiwara, Kosei Hasegawa, Ilan Bruchim, Dalia Tsoref, Katsutoshi Oda, Aikou Okamoto, Takayuki Enomoto, Dayana Michel, Hee‐Seung Kim, Jung‐Yun Lee, Asima Mukhopadhyay, Dionyssios Katsaros, Nicoletta Colombo, Sandro Pignata, Domenica Lorusso, Giovanni Scambia, Elise C. Kohn, Jungmin Lee, Iain A. McNeish, Shibani Nicum ほか 16 名 - The Lancet Oncology 2022 被引用: 142

  18. MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 被引用: 153

  19. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Susana Banerjee, Massimo Barberis, M.P. Barretina Ginesta, J.F. Baurain, Margherita Bignami, Line Bjørge, Paweł Blecharz, Ilan Bruchim, ME Capilna, Nicoletta Cerana, Americo Cicchetti, Dearbhaile Catherine Collins, Nicole Concin, Maurizio D’Incalci, Brittany A. Davidson, Thibault De La Motte Rouge, Pierandrea De Iaco, Fuat Demirkıran, Hannelore Denys, Thilo Doerk, Anne Dørum, Annamaria Ferrero, Alejandro Perez Fidalgo, Maurizio Genuardi, Laurence Gladieff, Rosalind Glasspool, Christoph Grimm, Murat Gültekin, E. Hahnen, Annette Hasenburg, Alinta Hegmane, Viola Heinzelmann, Estrid Høgdall, Ramūnas Janavičius, Sonata Jarmalaitė, Roshni Kalachand, Radka Kaneva, Saadettin Kılıçkap, Roman Kocián, D. Kolencik, Rebecca Kristeleit, Anna Kryzhanivska, Alexandra Léary, Birthe Lemley, Marjolijn J. L. Ligtenberg, José Antonio López‐Guerrero, Christopher J. Lord, E. Åvall‐Lundqvist, Johanna Mäenpää, Sven Mahner, Frederik Marmé, Christian Marth, Iain A. McNeish, Sabine Merkelbach‐Bruse, Marian J.E. Mourits, Nicola Normanno, Ana Oaknin, Kristiina Ojamaa, C. Papdimitriou, F. Penault-Llorca, Anna Myriam Perrone, Sandro Pignata, Eli Pikarsky, Étienne Rouleau, María Jesús Rubio, Anna Sapino, Barbara Schmalfeldt, Jalid Sehouli, Roni Shapira, Karina Dahl Steffensen ほか 12 名 - Annals of Oncology 2021 被引用: 164

  20. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

    著者: , , , , , , , , , , , , , , , - International Journal of Gynecological Cancer 2019 被引用: 400

  21. Treatment of recurrent ovarian cancer

    著者: , , , , - Annals of Oncology 2017 被引用: 354

  22. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sarper Toker, Stephen J. O’Keefe, Sandro Pignata, Linda Duska - The Lancet 2024 被引用: 161

  23. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gennaro Daniele, Francesco Perrone, Sandro Pignata, Domenica Lorusso, Florence Joly, Ciro Gallo, Nicoletta Colombo, Cristiana Sessa, Aristotelis Bamias, Vanda Salutari, Frédèric Selle, Simona Frezzini, Ugo De Giorgi, Patricia Pautier, Alessandra Bologna, Michele Orditura, C. Dubot, Angiolo Gadducci, Serafina Mammoliti, I. L. Ray-Coquard, Elena Zafarana, Enrico Breda, Laure Favier, Antonio Ardizzoia, Saverio Cinieri, R. Largillier, Daniela Sambataro, Emmanuel Guardiola, Rossella Lauria, Carmela Pisano, Francesco Raspagliesi, Giovanni Scambia, Gennaro Daniele, Francesco Perrone - The Lancet Oncology 2021 被引用: 149

  24. Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse

    著者: , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2010 被引用: 572